Login
Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc.

kyvernatx.com

What Do They Do?

Develops modified T-cell treatments for patients with autoimmune diseases, including stiff person syndrome and generalized myasthenia gravis.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −14% (Loss)
vs −$36.8M in Q3 FY2025
  • May 14, 2026 Kyverna appointed Gregory Martini as CFO Gregory Martini succeeded Marc Grasso, who will consult during the transition.

Who Do They Compete With?

Competes with Roche Holding, AbbVie, Johnson & Johnson, Bristol Myers Squibb, Novartis, Cabaletta Bio, and Cartesian Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support